Pretreatment with an anti-CGRP monoclonal antibody attenuates mild TBI-induced tactile hypersensitivity in mice
Abstract Background Post-traumatic headache (PTH) can develop following a mild traumatic brain injury (mTBI), such as a concussion. It is especially common among active-duty military personnel, Veterans, and athletes. The high prevalence and chronic nature of PTH highlight the importance of studying...
Saved in:
| Main Authors: | Anne-Sophie Wattiez, Adisa Kuburas, William C. Castonguay, Kim Fejgin, Ib V. Klewe, Andrew F. Russo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | The Journal of Headache and Pain |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s10194-025-02108-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of anti-CGRP(r) monoclonal antibodies in real clinical practice: preliminary analysis after three months of therapy
by: N. V. Vashchenko, et al.
Published: (2021-12-01) -
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
by: Gabriel Taricani Kubota
Published: (2022-08-01) -
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01) -
Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study
by: Marina de Tommaso, et al.
Published: (2025-05-01) -
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01)